SecBot SecBot

NVS drug pipeline

NOVARTIS AG · 21 rated drugs
$160.50
+0.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.9%
1-day, median of 34 events
IV rank
No data
No current options data
Rated drugs
21
3 bearish · 2 mixed · 16 neutral
Phase 3 trials
14
0 with results posted

Upcoming catalysts

9 dated
  1. Dec 14, 2026
    AAA617
    Phase 2 primary completion
  2. Dec 23, 2026
    AAA617
    Phase 2 primary completion
  3. Dec 30, 2026
    everolimus
    Phase 3 primary completion
  4. Dec 30, 2026
    Fabhalta
    Phase 2 primary completion
  5. Jan 25, 2027
    JDQ443
    Phase 2 primary completion
  6. Jan 28, 2027
    Alpelisib
    Phase 3 primary completion
  7. Jan 29, 2027
    Alpelisib
    Phase 2 primary completion
  8. Feb 1, 2027
    LEE011
    Phase 2 primary completion
  9. Feb 2, 2027
    LXH254
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (marketed); additional Phase 3 programs completed/terminated
Time to marketAlready marketed — approved in the US since January 2015; label-expansion filings for PMR/GCA are possible but no submission or decision date is recorded.

Cosentyx secukinumab Updated Aug 20

What to watch

Watch for Novartis disclosures on the completed PMR (381 patients, primary completion Sept 2025) and GCA (354 patients) Phase 3 programs, a regulatory submission for either would be the next meaningful Cosentyx catalyst, though it would move a ~$156 mega-cap modestly. Also track IL-17 competition and any biosimilar entry, plus the next quarterly 6-K for Cosentyx sales trajectory.

Bull case
  • Established commercial franchise: original FDA approval recorded 2015-01-21, plus an Oct 2023 FDA approval catalyst and a March 2025 supplemental approval (labeling) for the IV injectable, evidence of a durable, multi-indication product.
  • Pipeline optionality: two completed Novartis Phase 3 programs, polymyalgia rheumatica (381 enrolled, completed Feb 2026) and giant cell arteritis (354 enrolled, completed Feb 2026), could support new label expansions if results are positive, extending the product's lifecycle.
  • Parent is financially deep and diversified: NVS traded at ~$156.24 (2026-08-20) with analyst mean price target of $157.15 and 16 of 34 ratings at Buy/Strong Buy per the latest consensus snapshot, limited single-drug downside risk for holders.
Bear case
  • No near-term binary: as an approved drug with no scheduled PDUFA/readout, there is little dated upside catalyst; completed PMR/GCA trials have results 'not yet posted' and any submission timing is unannounced.
  • Mixed expansion record: Phase 3 trials in thyroid eye disease (28 patients) and rotator cuff tendinopathy (33 patients) were TERMINATED, showing the label-expansion strategy does not always pay off.
  • Competitive erosion risk: the IL-17/inflammation space is crowded (e.g., UCB's bimekizumab was run head-to-head vs secukinumab in a completed 743-patient Phase 3 psoriasis trial) and biosimilar pressure is a standing risk for an aging biologic.
● neutral
Impact
PhaseFiled/PDUFA (BLA under Priority Review, Accelerated Approval pathway)
Time to marketPDUFA decision expected around March 2027 (Priority Review, 6-month clock from September 8, 2026 BLA acceptance). If approved, commercial launch would follow weeks to months after.

del-zota delpacibart zotadirsen Updated Oct 27

What to watch

The next catalyst is the FDA's decision on del-zota's BLA under Priority Review (Accelerated Approval pathway). Novartis has not disclosed the exact PDUFA date, but with Priority Review's 6-month clock from the September 8, 2026 acceptance, a decision is expected around March 2027. An approval would mark the first approved exon 44 skipping therapy for DMD; a Complete Response Letter would pressure the Avidity acquisition thesis and the broader neuromuscular pipeline.

Bull case
  • There are no approved exon 44 skipping therapies for DMD, del-zota would be first-to-market for this specific mutation subset, addressing a clear unmet need.
  • Phase 1/2 EXPLORE44 data showed statistically significant exon 44 skipping (up to 67%), increased dystrophin expression, and decreased CK biomarkers, with an acceptable safety profile, published in The Lancet Neurology.
  • The FDA granted Breakthrough Therapy, Priority Review, Fast Track, Orphan Drug, and Rare Pediatric Disease designations, signaling strong regulatory alignment.
Bear case
  • The Phase 3 confirmatory trial (SAFARI44) is still recruiting, the BLA rests on Phase 1/2 data (26 patients), and the FDA's Accelerated Approval pathway requires a confirmatory study; if the confirmatory trial fails or is delayed, approval could be withdrawn or limited.
  • Novartis's other Avidity-acquired asset, del-desiran, failed its Phase 3 HARBOR study in DM1 on September 8, 2026, the same day del-zota's BLA acceptance was announced, raising questions about the broader AOC platform's clinical validity.
  • For a company the size of Novartis (~$200B+ market cap), del-zota is a small pipeline component; even a full approval would have limited impact on the stock.
● neutral
Impact
PhaseApproved (marketed); Phase 3 readout pending in aHUS
Time to marketAlready on the market (approved per FDA catalyst record dated 2023-12-05); potential aHUS label expansion depends on the pending Phase 3 readout and a future regulatory filing.

Fabhalta iptacopan Updated Aug 20

What to watch

Watch for the pending Phase 3 aHUS (atypical hemolytic uremic syndrome) topline readout from trial NCT04889430, which completed April 11, 2026 and was flagged "results pending, data readout imminent" in the local events ledger, a positive result could support a label-expansion filing, but the trial is only ~34 patients and Fabhalta is one product inside a ~$200B mega-cap, so expect only a modest NVS move. Also monitor Novartis quarterly commentary on Fabhalta sales ramp and any follow-on safety labeling after the June 2026 boxed-warning update.

Bull case
  • First-in-class ORAL complement Factor B inhibitor (FDA data: route ORAL), a convenient pill versus injected complement therapies in chronic orphan blood/kidney diseases.
  • Already FDA-approved and commercial (FDA approval catalyst recorded 2023-12-05), so it is generating revenue, not a development-stage risk.
  • Label-expansion optionality: Phase 3 aHUS trial (NCT04889430, 34 patients) completed 2026-04-11 and results are flagged 'imminent', a positive readout could support a new indication filing.
Bear case
  • June 2026 FDA safety labeling added a boxed warning: serious, potentially fatal encapsulated-bacteria infections (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b), a real safety/marketing overhang.
  • The pending aHUS readout is small (34 patients) and unproven; a miss would not only kill that expansion but dent the 'oral complement franchise' narrative.
  • Tiny stock-level impact: at a ~$200B mega-cap, Fabhalta, let alone a 34-patient niche trial, is a minor value driver; historically NVS FDA-approval catalysts moved the stock only single-digit (e.g., +6.1% 1-day around RHAPSIDO approval 2025-09-30).
◆ mixed
Impact
PhasePhase 3
Time to marketUncertain for Sjögren's — submission status unclear as of Oct 2026; if filed, potential FDA decision in H2 2027. ITP submission planned for 2027 pending VAYHIT1 data. SLE likely 2028 or later.

ianalumab Updated Oct 27

What to watch

Watch for any Novartis announcement confirming the Sjögren's regulatory submission, if filed, a PDUFA date would likely land in H2 2027. Also monitor VAYHIT1 topline data (first-line ITP), which could trigger the ITP regulatory submission in 2027. The NEJM publication and mixed efficacy signal may increase regulatory uncertainty.

Bull case
  • First-ever targeted therapy for Sjögren's disease, a multi-billion-dollar unmet need with no approved disease-modifying treatments
  • Phase 3 NEPTUNUS trials met primary endpoint (ESSDAI reduction) in replicate studies, a first for any drug in Sjögren's
  • FDA Breakthrough Therapy designation (Jan 2026) provides accelerated development and rolling review pathway
Bear case
  • NEJM-published data (Oct 22, 2026) showed only modest 1-1.3 point ESSDAI improvement vs placebo; key secondary endpoints like patient-reported symptoms did not reach statistical significance
  • Regulatory submission for Sjögren's was pushed from early 2026 to Q3 2026, and as of late October 2026 it remains unclear whether the filing was actually made, creating timeline uncertainty
  • High placebo response in NEPTUNUS trials complicates the efficacy signal and may give FDA pause
● neutral
Impact
PhaseApproved (pivotal Phase 3 ASCEMBL completed; additional Phase 2/3 studies mostly completed or terminated)
Time to marketAlready marketed — FDA approval recorded October 29, 2021 (local FDA-catalyst ledger); commercial launch has been under way since.

Scemblix asciminib Updated Aug 20

Bull case
  • Approved and commercially proven: FDA approval catalyst for SCEMBLIX recorded 2021-10-29; pivotal Phase 3 ASCEMBL (asciminib vs bosutinib in 2+ prior-TKI CML) completed with results (n=233).
  • Fast-growing franchise: Q2 2026 Scemblix net sales +89% in constant currency, per the LLM analysis of Novartis' 6-K filed 2026-07-21, one of the company's top growth drivers.
  • First-in-class niche: described as a first-in-class CML treatment (Certara press release summary), which supports durable positioning for patients who fail multiple TKIs.
Bear case
  • No binary catalyst: no upcoming FDA catalyst rows exist in local data for NVS, and Scemblix is already approved, commercial ramp (however strong) is not a hard share-price catalyst.
  • Small part of a huge company: Scemblix sits inside a ~$285B market-cap, $14.4B/quarter revenue pharma, so even +89% drug growth has limited effect on NVS share price.
  • Development setbacks in the program: Phase 3 NCT05413915 and Phase 2 NCT04216563 / NCT03874858 asciminib studies were TERMINATED in the local trial ledger.
● neutral
Impact
PhasePhase 3
Time to marketUnknown; the sole remaining Phase 3 trial (LILAC-TIMI 76) is still recruiting with estimated completion in December 2027, meaning any potential regulatory filing is likely 3+ years away at best.

abelacimab Updated Oct 27

What to watch

The next catalyst is the LILAC-TIMI 76 Phase 3 readout (abelacimab vs placebo in AF patients unsuitable for oral anticoagulation), but with estimated completion in December 2027, no near-term binary is on the calendar. For a mega-cap like Novartis, abelacimab is a small pipeline component; the cancer-trial failures are already priced in. Watch for any interim LILAC analysis or regulatory guidance, but the next hard catalyst is likely 12+ months away.

Bull case
  • Phase 2 AZALEA-TIMI 71 (published NEJM Jan 2025) showed abelacimab reduced bleeding events by 67% vs rivaroxaban in atrial fibrillation patients, a potentially best-in-class safety signal.
  • The LILAC-TIMI 76 trial targets a large unmet need: AF patients who cannot take oral anticoagulants, a population with no good options today.
  • Abelacimab is a once-monthly subcutaneous injection, which could offer compliance advantages over daily oral pills.
Bear case
  • Two Phase 3 cancer-associated thrombosis trials (ASTER vs Eliquis and a dalteparin study) were terminated in early 2026 after abelacimab failed to beat Eliquis, raising questions about the drug's efficacy in high-risk populations.
  • The remaining Phase 3 LILAC-TIMI 76 trial is still recruiting with estimated completion not until December 2027, years away from any potential regulatory filing.
  • Novartis paid $925M upfront (up to $3.1B total) for Anthos in 2025, and the cancer-trial failures have already narrowed the drug's addressable market significantly.
▼ bearish
Impact
PhasePhase 3 (completed, failed primary endpoint)
Time to marketUnknown — the Phase 3 trial failed its primary endpoint, and no regulatory submission path has been determined. The drug may be years away or may never reach market.

del-desiran delpacibart etedesiran Updated Oct 27

What to watch

The Phase 3 HARBOR trial has already failed, and no regulatory submission or next pivotal readout is scheduled. Watch for Novartis's full data presentation at a medical conference and any decision on whether to pursue a regulatory path based on secondary endpoints, either outcome would be incremental for a stock with a $200B+ market cap and dozens of marketed products.

Bull case
  • Novartis reported 'evidence of clinical activity' in secondary endpoints and exploratory analyses, suggesting the drug may have biological effect that could be captured with a different trial design or endpoint
  • DM1 has zero approved treatments and high unmet need, any therapy showing meaningful benefit could still find a regulatory path
  • The antibody-oligonucleotide conjugate platform (AOC) could be validated for other indications even if the DM1 program needs redesign
Bear case
  • The Phase 3 HARBOR trial failed its primary endpoint of vHOT with no statistical significance versus placebo, a clear binary failure for the lead asset of the ~$12B Avidity acquisition
  • Novartis shares dropped ~14% on the news (one of the worst single-day declines in company history), reflecting investor disappointment and lost confidence in the deal thesis
  • The failure raises questions about the broader AOC platform and Novartis's dealmaking strategy, especially coming on the heels of the pelacarsen Phase 3 miss days earlier
▼ bearish
Impact
PhaseApproved / marketed (adult HFrEF, 2015; pediatric heart failure via Entresto Sprinkle, 2024). No pending pivotal trials
Time to marketAlready approved and marketed — adult heart-failure approval July 2015; pediatric formulation (Entresto Sprinkle) approved April 2024. US brand exclusivity has ended; the drug is now in generic-driven patent-cliff decline. No pending approvals.

Entresto sacubitril and valsartan Updated Aug 20

What to watch

Watch quarterly Entresto sales in Novartis earnings: Q2 2026 showed -51% constant-currency decline from US generics, and the question is how fast the erosion flattens and how much generic share stabilizes. Note that this is a well-known, largely priced-in headwind offset by growth in Kisqali, Kesimpta, Scemblix and Pluvicto; short interest is low (~0.27% of estimated shares outstanding, 2.7 days to cover per the latest FINRA settlement), so there is no squeeze dynamic here.

Bull case
  • Still a standard-of-care heart-failure medicine: FDA approval catalysts are recorded for 2015-07-07 (Entresto) and 2024-04-12 (Entresto Sprinkle), and the drug remains marketed globally with a pediatric formulation.
  • The downside is largely disclosed and visible: Q2 2026 6-K explicitly quantifies Entresto at -51% cc on US generics, and Novartis is simultaneously growing Kisqali (+43% cc), Kesimpta (+32% cc), Scemblix (+89% cc) and Pluvicto (+43% cc), limiting stock-level damage.
  • Investor positioning on the ADR is not crowded bearish: FINRA short interest was ~5.24M shares (~0.27% of estimated shares outstanding, ~2.69 days to cover) as of the 2026-07-31 settlement.
Bear case
  • US generic entry has ended the growth story: Q2 2026 results show Entresto sales down -51% in constant currency year-over-year, and the filing's risk list flags 'Entresto sales declining ~50% YoY due to US generics' as a major headwind to total revenue.
  • No upcoming hard catalyst for this drug, the approval binaries (2015, 2024) already passed and no Novartis-sponsored pivotal readout or PDUFA is scheduled for Entresto in the local data; remaining studies are investigator-initiated and Novartis's own XXB750 heart-failure program (with sacubitril/valsartan as comparator) was terminated.
  • July 2026 FDA safety-labeling action added a boxed warning for fetal toxicity (drugs acting on the renin-angiotensin system can cause fetal injury/death), a labeling overhang.
● neutral
Impact
PhaseApproved (marketed); label-expansion programs: Phase 3 (AOSD, Japan) completed; Phase 3 (first-line NSCLC) terminated
Time to marketAlready marketed: US FDA approval recorded 2009-06-17 (SEC-extracted catalyst data). No new market entry pending per available data; the completed Phase 3 AOSD study (Japan) is a label-expansion candidate whose regulatory outcome was not disclosed in the sources.

Ilaris canakinumab Updated Aug 20

What to watch

Treat Ilaris as a mature cash-flow product, not a binary, the big upside experiment (first-line lung cancer) was terminated, and no FDA decision is pending. The only share-price-relevant news to watch is Novartis' quarterly reporting (6-K/20-F) for Ilaris sales momentum, any label expansion or divestiture headlines, and broader NVS catalysts like the Phase 3 KRAS-lung-cancer readout (JDQ443) due around August 2026.

Bull case
  • Ilaris is a long-approved, marketed product: SecBot's SEC-extracted catalyst data records an FDA approval on 2009-06-17, with a +2.27% one-day stock move around it.
  • Novartis still invests in the asset, a Phase 3 study of canakinumab in Japanese adult-onset Still's disease patients (NCT04717635) completed with results in April 2025, supporting a possible label expansion in an autoinflammatory indication.
  • The sponsor is a profitable megacap with broadly neutral-to-positive analyst coverage: consensus shows 6 strongBuy and 10 buy vs 4 sell (period 2026-08-01), Morgan Stanley maintained Overweight in March 2026, and JPMorgan added to its NVS position (+25.5% share change) in Q2 2026 (13F-derived).
Bear case
  • The main growth catalyst failed: the 673-patient Phase 3 study adding canakinumab to pembrolizumab + chemo in first-line advanced NSCLC (NCT03631199) is recorded as TERMINATED, killing the large oncology upside thesis.
  • No hard, dated binary ahead: no FDA catalyst or pivotal readout for canakinumab appears in the next ~12 months of SecBot data, so the stock has little to react to from this drug.
  • Institutional trimming in the latest 13F quarter (2026-Q2, delayed data): Goldman Sachs -54.3%, UBS -33.9%, Dodge & Cox near-exit -89.1%, Point72 -62.6%, and Renaissance Technologies -29.1% share changes, while the analyst price-target mean (~$157.15) sits near the current price with only ~2.5% implied upside.
● neutral
Impact
PhaseApproved / marketed
Time to marketAlready on the market with significant commercial sales (court record cites annual sales exceeding $500M). The open timing question is generic entry: Lantheus's ANDA No. 217060 is pending FDA action, and Novartis's appeal of the patent-invalidity ruling is estimated to take 1-2 years.

Lutathera lutetium lu 177 dotatate Updated Aug 20

What to watch

For NVS holders this is a watch-item, not a thesis-driver: Lutathera is one of ~30 tracked drugs and immaterial to the stock, which is why the Q2 2026 filing flags it only as a risk item. The tradeable angle is elsewhere, Lantheus (LNTH) won the Delaware ruling and is itself being acquired by Curium ($102.50/share cash + up to $12 CVRs, close expected H1 2027), so the generic-commercialization story will land inside a private company. Watch the Federal Circuit appeal and FDA action on Lantheus ANDA 217060 for timing of any U.S. generic entry.

Bull case
  • Lutathera is an approved, marketed product with significant commercial sales, the court record cites annual sales exceeding $500M, and it is part of Novartis's radioligand franchise, whose larger asset Pluvicto grew +43% cc in Q2 2026 per the NVS 6-K.
  • The patent loss is not final: the NVS Q2 2026 filing confirms an appeal has been filed, and the court record flags a 1-2 year appeal timeline with a 'high' likelihood, a Federal Circuit reversal would restore exclusivity.
  • Institutional accumulation in NVS was visible in 2026-Q2 (e.g., JPMorgan added +25.5%, Citadel and Millennium opened new positions per 13F-change data), and FINRA short interest is tiny (~0.27% of estimated shares outstanding as of the 2026-07-31 settlement), so there is no heavy short overhang betting against the name.
Bear case
  • All four asserted Lutathera patents were found invalid under the on-sale bar (U.S. 10,596,276; 12,151,003; 12,168,063; 12,161,732), the court found ADACAP's pre-July 2017 European expanded-access sales were commercial, not experimental, which is a fact-intensive finding the appeal will struggle to overturn.
  • Generic competition is now plausible: Lantheus's ANDA 217060 was cleared of the patent barrier, and Curium's competing product was found not to infringe any asserted claim, a generic/competitive entry would erode Lutathera's U.S. sales.
  • For the NVS stock the drug is immaterial: it is one of ~30 tracked drugs in a company with $14.4B quarterly net sales, so even a total loss of U.S. exclusivity moves NVS only marginally, no squeeze or binary upside for the stock.
● neutral
Impact
PhasePhase 2 (completed)
Time to marketRegulatory filing projected in or after 2029 per AdisInsight; potential approval would be several years later if Phase 3 succeeds, putting commercialization likely in the early 2030s at the earliest.

pacibekitug Updated Oct 27

What to watch

The next catalyst is the initiation of the Phase 3 cardiovascular outcomes trial, which Novartis has signaled it plans to run but has not yet formally announced a start date. A trial start announcement or design details could provide a modest positive catalyst. Conversely, if Novartis decides to deprioritize or redesign the program following the ziltivekimab failure, that would be a negative signal. Given the drug is still pre-Phase 3 and Novartis is a $200B+ diversified pharma, pacibekitug alone is unlikely to drive a major share-price move in either direction over the next 12 months.

Bull case
  • Phase 2 TRANQUILITY data showed pacibekitug reduced hs-CRP by 76-89% through six months with only a 2% discontinuation rate and no dose-related safety signals, a clean profile for a quarterly subcutaneous injection.
  • Novartis argues pacibekitug is differentiated from ziltivekimab: it directly binds IL-6 ligand (not the receptor), has a longer half-life enabling quarterly dosing, and may avoid the paradoxical IL-6 increases seen with receptor blockers.
  • Novartis paid $1.4B to acquire Tourmaline Bio specifically for this asset, signaling strong internal conviction. The drug was described as 'Phase 3-ready' at acquisition.
Bear case
  • Competitor ziltivekimab (Novo Nordisk) failed its Phase 3 ZEUS cardiovascular outcomes trial in August 2026 (HR 0.99; no MACE reduction), casting doubt on the entire IL-6/cardiovascular hypothesis that pacibekitug depends on.
  • The Phase 2 TRANQUILITY trial measured only biomarkers (hs-CRP), not hard cardiovascular endpoints. Whether biomarker reductions translate into fewer heart attacks or strokes remains unproven.
  • Novartis also saw its own pelacarsen (Lp(a) drug) fail a large Phase 3 outcomes trial in September 2026, raising questions about the company's cardiovascular pipeline strategy.
● neutral
Impact
PhasePhase 3
Time to marketEU submission completed in Q3 2026; potential EU approval in 2027-2028. US/Japan/China filings delayed pending additional Phase 3 data — launch estimated 2027 or later per Novartis CEO.

pelabresib Updated Oct 27

What to watch

The next catalyst is the EU regulatory decision on pelabresib for myelofibrosis, following the Q3 2026 submission, a typical EMA review takes 12-18 months, so a decision could come in late 2027 or 2028. The ongoing MANIFEST-3 Phase 3 trial (NCT07357727) started May 2026 with 460 patients and completion expected December 2030; interim safety data will be critical to resolving the AML transformation signal. For Novartis, even a positive EU approval would be a modest contributor given the company's diversified portfolio.

Bull case
  • Phase 3 MANIFEST-2 met its primary endpoint with high statistical significance (66% vs 35% spleen response, p<0.001), demonstrating clear efficacy
  • 96-week follow-up data showed durable and deepening responses in spleen volume, symptoms, and anemia
  • EU submission completed in Q3 2026, marking the first regulatory filing for the drug
Bear case
  • Safety signal, imbalance in malignant transformations to acute myeloid leukemia in pelabresib-treated patients, caused Novartis to delay US/Japan/China filings by years
  • Novartis took an $800M impairment on the $2.9B MorphoSys acquisition, signaling reduced confidence in the asset's value
  • A new Phase 3 trial (MANIFEST-3) was required, pushing potential US approval to 2027 or later
● neutral
Impact
PhasePhase 3 / approved-stage (FDA catalyst record 2025-09-30; EU opinion Feb 2026)
Time to marketUS: already at commercial/approved stage per the FDA catalyst record (2025-09-30). EU: authorisation decision pending after the Feb 2026 opinion. CINDU label expansion still in Phase 3 (study estimated to complete ~2029).

Rhapsido remibrutinib Updated Aug 20

What to watch

The next potential re-rating events are the CINDU Phase 3 topline (est. primary completion was 2026-05-22; no results posted yet in the data) and the EU authorisation decision that normally follows a CHMP opinion, but neither is a dated binary in hand, so there is no scheduled single-day catalyst to trade. Given Rhapsido's small weight inside Novartis, treat it as pipeline news flow rather than a standalone stock thesis, and re-verify approval/sales claims with external sources once web search is available.

Bull case
  • FDA/OPENFDA records show NDA 218436 for remibrutinib classified as a 'fda_approval' catalyst (Type 1 new molecular entity) dated 2025-09-30 with high confidence, indicating US regulatory success and launch.
  • NVS shares rose +6.14% over 1 day and +6.68% over 5 days around that catalyst date (price ~120.43 before, ~127.83 after), consistent with a positive regulatory event.
  • European momentum: an EMA EPAR entry for 'Rhapsido, remibrutinib' shows Status: Opinion as of 2026-02-27, the step toward EU authorisation.
Bear case
  • External web verification was impossible this session, so actual approval status, prescription/sales ramp, and competition could not be confirmed, the catalyst outcome field is null and must not be read as an authoritative approval.
  • No confirmed hard, dated catalyst in the next ~12 months: the US decision date (2025-09-30) and EMA opinion (2026-02-27) are behind us, and the CINDU Phase 3 readout has no confirmed results/report date in the data.
  • Concentration is tiny: Rhapsido is one asset inside a mega-cap; even a large urticaria franchise is a small slice of Novartis's valuation, limiting single-drug share-price impact.
● neutral
Impact
PhaseApproved (FDA, Apr 2025). Locally tracked clinical data shows a completed Phase 2 atrasentan study in IgA nephropathy (N
Time to marketAlready on the market — FDA approval catalyst recorded 2025-04-02.

Vanrafia atrasentan Updated Aug 20

What to watch

Watch quarterly 6-Ks for Vanrafia's first full-year sales trajectory and any label-expansion or new atrasentan readouts (the Phase 2 crossover study completed Oct 2025, so a publication/next-trial update could come). But treat Vanrafia as immaterial to NVS's share price, the stock trades on the broader portfolio (Kisqali/Pluvicto growth, Entresto generic erosion, pipeline catalysts), not on this single niche product.

Bull case
  • Already FDA-approved (approval catalyst dated 2025-04-02 for NVS), no approval risk remains; the stock actually rose +2.42% the day after the approval record (price 106.37 -> 108.94).
  • Atrasentan is a clinically validated molecule in IgA nephropathy: the local ClinicalTrials.gov record shows a completed, results-bearing Phase 2 randomized crossover study (NCT05834738, n=54) sponsored by Novartis Pharmaceuticals.
  • Vanrafia is named in Novartis's Q2 2026 earnings 6-K (net sales $14.4B), meaning it is being commercialized with a mega-cap company's infrastructure and reach.
Bear case
  • A June 2026 FDA safety-labeling action imposed a boxed embryo-fetal toxicity warning: Vanrafia is contraindicated in pregnancy and requires pregnancy exclusion plus contraception (and 2 weeks after stopping), a real hurdle for a kidney disease that disproportionately affects younger patients and women of childbearing age.
  • Vanrafia is a small part of the thesis: it does not appear among the Q2 2026 growth drivers Novartis highlighted (Kisqali +43%, Kesimpta +32%, Scemblix +89%, Pluvicto +43%, Leqvio +59% cc), and its approval catalyst was followed by a -6.15% five-day move.
  • No new dated binary catalyst for Vanrafia is scheduled in the next ~12 months, so there is no obvious near-term event to re-rate the stock on this drug.
● neutral
Impact
PhasePhase 3
Time to marketAt least 3-5 years; Phase 3 BEYOND trial estimated to complete Jan 2028, followed by regulatory filing and review.

zigakibart Updated Oct 27

What to watch

The next meaningful catalyst is the Phase 3 BEYOND primary completion (estimated Aug 2027) or any potential interim analysis. For a large-cap like Novartis, zigakibart alone is unlikely to drive material share-price moves. Watch for topline BEYOND results and any accelerated approval filing strategy, but this is a multi-year story within a diversified pharma portfolio.

Bull case
  • Phase 1/2 data published in Kidney International showed zigakibart reduced proteinuria by ~60% and stabilized eGFR over 100 weeks, with a well-tolerated safety profile, a potentially disease-modifying profile in a progressive kidney disease.
  • 124-week data presented at ASN Kidney Week 2026 (Oct 23) showed sustained proteinuria remission and durable biomarker suppression (Gd-IgA1, IgA), reinforcing the drug's long-term potential.
  • Novartis already has a strong IgAN franchise with Fabhalta (approved Jul 2026) and atrasentan (Vanrafia, Phase III data at ERA 2026), creating potential for combination strategies like the planned LUMINA IgAN trial of zigakibart + atrasentan.
Bear case
  • Crowded IgAN market, at least 7 FDA-approved drugs (Tarpeyo, Filspari, Fabhalta, Ultomiris, etc.) already compete, and Vertex's povetacicept has a PDUFA date of Nov 30, 2026, meaning zigakibart could enter a market with multiple entrenched options.
  • Phase 3 BEYOND trial won't read out until ~Aug 2027 at the earliest, so no near-term regulatory catalyst; the drug is years from potential commercialization.
  • As a subcutaneously injected monoclonal antibody, zigakibart faces a convenience disadvantage versus oral competitors like Tarpeyo (budesonide), Filspari (sparsentan), and Fabhalta (iptacopan).
● neutral
Impact
PhaseApproved
Time to marketAlready on the market — FDA-approved since 2007 (Exforge) and 2009 (Exforge HCT)

Exforge amlodipine / valsartan Updated Aug 21

What to watch

There is nothing tradeable in Exforge itself: the approval binary passed in 2007 and the brand is long generic-eroded, so watch NVS for pipeline events (oncology/immunology readouts), not this drug.

Bull case
  • Exforge remains an approved, marketed product (FDA approval recorded 2007-06-20), so it contributes legacy brand revenue and requires no further regulatory risk to be on the market.
  • The combination approach (two mechanisms in one pill) is a clinically durable concept; the three-drug Exforge HCT follow-on was also approved (2009-04-30), showing the franchise's depth.
  • NVS is a financially solid mega-cap: analyst snapshot shows 16 buy/strong-buy vs 4 sell calls and a mean price target of $157.15 vs a $156.24 price, implying roughly flat near-term upside.
Bear case
  • Exforge has no pending FDA decision, pivotal readout, or other hard catalyst, it cannot drive a binary share-price move, and local data shows no upcoming NVS FDA catalysts in the next 90 days.
  • Exforge is a tiny part of Novartis's pipeline, so even positive brand news would move NVS only marginally; several tracked 13F managers trimmed or exited NVS in 2026-Q2 (Goldman Sachs -54.3%, Dodge & Cox near-exit, UBS -33.9%).
● neutral
Impact
PhasePhase 2
Time to marketUnknown — the Alzheimer's Phase 2 trial is not expected to read out until at least late 2028, and if positive, would still require Phase 3 trials and regulatory filings, putting potential approval many years away.

lifonebart Updated Oct 27

What to watch

The ALS program has already been terminated, removing that binary risk. The Alzheimer's Phase 2 readout is the next meaningful catalyst but not expected until at least late 2028, too distant to drive near-term share price action for a company of Novartis's scale. Watch for detailed ALS data at the December 2026 ALS/MND symposium, though this is a retrospective disclosure on a dead program.

Bull case
  • TREM2 activation is a biologically validated target in Alzheimer's, loss-of-function TREM2 mutations (e.g., R47H) significantly increase Alzheimer's risk, supporting the rationale for an agonist approach
  • The Alzheimer's Phase 2 trial is still recruiting and Novartis chose to continue the Alzheimer's program even after the ALS failure, suggesting internal confidence in the AD indication
  • Preclinical data showed VHB937 activates microglial functions like chemotaxis and phagocytosis with sub-nanomolar affinity
Bear case
  • The ALS Phase 2 ASTRALS trial failed to meet primary or secondary endpoints, leading to program discontinuation, a significant negative signal for the TREM2 mechanism in neurodegeneration
  • The Alzheimer's Phase 2 readout is not expected until at least late 2028, meaning no near-term catalyst and years of development risk ahead
  • For Novartis, lifonebart is a tiny pipeline asset, even a positive Alzheimer's readout would have limited impact on a ~$200B market-cap stock
● neutral
Impact
PhaseApproved
Time to marketAlready marketed — approved since 1988 (Sandostatin) and 1998 (Sandostatin LAR)

Sandostatin octreotide Updated Aug 21

What to watch

Treat Sandostatin as immaterial to NVS: it is an approved, generics-eroded legacy drug with no scheduled binary catalyst, so it should not drive a trade. For anyone holding NVS, the stock's move will be set by the broader pipeline and earnings (consensus rating 'hold', mean price target $157.15 vs. ~$156.24 spot, per local analyst data), not by this product.

Bull case
  • Long-proven franchise: local FDA catalyst records show approvals in 1988 (Sandostatin) and 1998 (Sandostatin LAR), giving ~35 years of clinical track record as a standard-of-care in acromegaly and neuroendocrine tumors.
  • Generic supply disruption could temporarily favor the brand: FDA recall actions in 2026 show Teva's generic octreotide acetate LAR (ANDA210317) was pulled in multiple Class II recalls over lack of sterility assurance, which can create branded-demand spillover.
  • Negligible downside to NVS: with 2026 consensus revenue near $57.6B (local analyst estimates), Sandostatin is a minor legacy line, and the drug's erosion does not threaten the company's thesis.
Bear case
  • Mature, generic-eroded franchise: Teva's octreotide acetate is an approved generic of Sandostatin LAR (ANDA210317), and multiple additional generic entrants historically pressure branded sales, classic late-lifecycle revenue decline.
  • No pipeline catalyst: Novartis's own octreotide program outside approved indications was terminated (diabetic retinopathy Phase 3 stopped for 'inconsistent treatment benefit'), and Sandostatin has no pending regulatory action or label expansion.
  • Competitive headwinds: newer somatostatin analogues and a next-generation octreotide depot (CAM2029) with a completed Phase 3 in acromegaly (NCT04076462) compete for the same patients.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on the market (approved 2007); US generic competition began May 2025

Tasigna nilotinib Updated Aug 21

What to watch

For a Tasigna-specific trade, there is nothing binary to trade on: the patent cliff already happened (first US generic launched May 27, 2025). Watch Novartis quarterly reports for how fast nilotinib revenue erodes and whether generic share stabilizes, that is a slow bleed, not a catalyst. NVS itself is a diversified mega-cap (analyst consensus 'hold', mean price target ~$157.15 vs. ~$156.24 price), so Tasigna moves almost nothing in the stock; any Tasigna news is noise for NVS shareholders.

Bull case
  • Still a standard-of-care branded option in CML: approved for newly diagnosed chronic-phase Ph+ CML in adults and children ≥1 year and for resistance/intolerance to prior TKIs (Novartis US prescribing info; tasigna-hcp.com).
  • Established efficacy for ~18 years since the 2007 FDA approval, which was itself a positive catalyst for the stock.
  • Some market analysts note the branded product 'continues to command premium pricing in the United States and certain European markets' despite generic entry (dataintelo nilotinib market report).
Bear case
  • US exclusivity is gone: Tasigna lost exclusivity in 2025 with generic competition from Apotex, MSN Laboratories, and Hetero Labs; Apotex launched the first generic on May 27, 2025 with 180-day exclusivity (pharmalinkage; sohoinsider; Citeline).
  • Sales are declining and now a minor line for Novartis: 2024 US sales were $848M, and Novartis' Q4 2025 release flags 'significant US generic entries' pressuring results (pharmalinkage; Novartis Q4 2025 media release).
  • No growth catalyst: there is no pending PDUFA, pivotal readout, or label-expansion decision for Tasigna in SecBot's FDA catalyst data, and NVS has no upcoming FDA catalysts in the 180-day window.
◆ mixed
Impact
PhasePhase 3
Time to marketAt least 4-5 years, assuming Phase 3 success and regulatory filing around 2030-2031

votoplam Updated Oct 27

What to watch

The next hard catalyst is the Phase 3 INVEST-HD topline readout, expected around 2030, roughly 3+ years away. For Novartis, a $200B+ diversified pharma, votoplam is one of many pipeline assets; the readout is too distant and too small a concentration to drive a major share-price move. Watch for interim updates at medical conferences (e.g., 2027-2028) and any regulatory pathway clarity (accelerated approval discussions), but near-term stock movement from this drug alone is unlikely.

Bull case
  • Phase 2 PIVOT-HD met its primary endpoint with highly significant HTT protein reduction (p<0.0001) at Week 12, showing 23% reduction at 5mg and 36-39% at 10mg.
  • 24-month extension data showed dose-dependent slowing of disease progression: 52% at 10mg and 28% at 5mg on cUHDRS vs a matched natural-history cohort, the strongest signal seen in an HD disease-modifying trial.
  • Novartis validated the asset with a $1B upfront payment (up to $2.9B total), one of the largest neurology licensing deals, signaling high internal conviction.
Bear case
  • Phase 3 readout is not expected until ~2030, a distant, high-risk binary with no near-term catalyst for Novartis shares.
  • The Phase 2 data used a natural-history external control arm, not a concurrent placebo, which raises the bar for Phase 3 confirmation.
  • Huntington's disease trials have a history of failure (Roche's tominersen and RG6496 were both discontinued in July 2026), and disease-modifying endpoints remain unvalidated.
● neutral
Impact
PhaseApproved (genericized / off-patent legacy brand)
Time to marketAlready approved and long off-patent; the brand is superseded by generic valsartan from multiple manufacturers.

Diovan valsartan Updated Aug 21

What to watch

There is nothing to trade on Diovan itself, it is a generic commodity now. Investors watching Novartis should ignore this molecule and instead track the cardiovascular franchise via the sacubitril/valsartan combination (a separate product) plus pending pipeline readouts (e.g., BION-1301, iptacopan) that actually move NVS. Current NVS setup: price ~$156.24, analyst recommendation "hold" with mean target $157.15 (implied upside ~2.5%).

Bull case
  • Valsartan remains a standard-of-care blood-pressure agent with entrenched clinical use: FDA records show the molecule still being actively labeled (pharm class: Angiotensin 2 Receptor Blocker) with July–August 2026 safety-labeling updates, and it continues to appear as an active comparator in hypertension trials (NCT07700875).
  • The molecule's clinical franchise lives on inside Novartis's cardiovascular portfolio through the sacubitril/valsartan combination (a distinct product), which still shows up in Phase 2/3 trials mapped to NVS in the local pipeline data, a modest franchise halo, not a Diovan catalyst.
Bear case
  • Fully genericized: every recent FDA action row for valsartan is a generic Abbreviated New Drug Application holder (Ohm Laboratories ANDA077492; Umedica Laboratories ANDA219946 for sacubitril/valsartan), not the branded Diovan, no proprietary brand economics remain.
  • Zero scheduled catalysts: no FDA catalyst rows, no catalyst-outcome history, no press releases, and no Novartis-sponsored trials for Diovan/valsartan in this session's data, there is no binary event to trade.
  • Immaterial to the stock: NVS is a mega-cap trading at ~$156.24 with a 'hold' analyst consensus (mean price target $157.15, implied upside ~2.5% per local consensus data); Diovan is not part of the investment thesis and cannot move the share price.

Other drugs in filings and trials

no drug report yet
  • VIJOICE Last: Approval · Apr 24, 2024
  • XROMI Last: Approval · Apr 4, 2024
  • MEKINIST Last: Approval · Mar 16, 2023
  • PLUVICTO Last: Approval · Mar 23, 2022
  • LEQVIO Last: Approval · Dec 22, 2021
  • TABRECTA Last: Approval · May 6, 2020
  • ADAKVEO Last: Approval · Nov 15, 2019
  • BEOVU Last: Approval · Oct 7, 2019
  • PIQRAY Last: Approval · May 24, 2019
  • MAYZENT Last: Approval · Mar 26, 2019
  • ZYKADIA Last: Approval · Mar 18, 2019
  • EGATEN Last: Approval · Feb 13, 2019
  • JADENU SPRINKLE Last: Approval · May 18, 2017
  • KISQALI FEMARA CO-PACK (COPACKAGED) Last: Approval · May 4, 2017
  • RYDAPT Last: Approval · Apr 28, 2017
  • KISQALI Last: Approval · Mar 13, 2017
  • SEEBRI NEOHALER Last: Approval · Oct 29, 2015
  • PROMACTA KIT Last: Approval · Aug 24, 2015
  • JADENU Last: Approval · Mar 30, 2015
  • IZBA Last: Approval · May 15, 2014
  • PURIXAN Last: Approval · Apr 28, 2014
  • ADASUVE Last: Approval · Dec 21, 2012
  • AFINITOR DISPERZ Last: Approval · Aug 29, 2012
  • 20 mg baclofen vaginal suppository daily per vagina 1 trial
  • CPK850 1 trial
  • everolimus 1 trial
  • LDK378 1 trial
  • LEE011 1 trial
  • NGI226 1 trial
  • Pelacarsen 1 trial
  • Ribociclib 2 trials
  • Sacubitril-valsartan 1 trial
  • TIN816 70 mg lyophilisate powder 1 trial
  • TQJ230 2 trials
  • Trametinib tablet 1 trial
  • YTB323 1 trial

Past FDA events & how the stock moved

34 events
DateDrugEvent1 day5 days
Sep 30, 2025RhapsidoApproval+6.1%+6.0%
Apr 2, 2025VanrafiaApproval+2.4%−5.3%
Apr 24, 2024VIJOICEApproval+1.8%+0.2%
Apr 12, 2024EntrestoApproval+0.1%+0.0%
Apr 4, 2024XROMIApproval+1.5%−0.0%
Dec 5, 2023FabhaltaApproval−2.0%−0.8%
Oct 6, 2023CosentyxApproval+1.5%+1.1%
Mar 16, 2023MEKINISTApproval+0.1%+0.5%
Apr 5, 2022VIJOICEApproval+3.8%+6.1%
Mar 23, 2022PLUVICTOApproval+0.8%+2.4%
Dec 22, 2021LEQVIOApproval+0.8%+1.7%
Oct 29, 2021ScemblixApproval+0.9%+0.4%
May 6, 2020TABRECTAApproval−0.1%+0.5%
Nov 15, 2019ADAKVEOApproval+0.9%+1.1%
Oct 7, 2019BEOVUApproval−0.7%−0.0%
May 24, 2019PIQRAYApproval+2.9%+3.8%
Mar 26, 2019MAYZENTApproval+1.9%+1.7%
Mar 18, 2019ZYKADIAApproval−0.3%+0.0%
Feb 13, 2019EGATENApproval+0.2%+1.9%
May 18, 2017JADENU SPRINKLEApproval+0.7%+1.9%
May 4, 2017KISQALI FEMARA CO-PACK (COPACKAGED)Approval+0.3%+1.5%
Apr 28, 2017RYDAPTApproval−0.1%+1.0%
Mar 13, 2017KISQALIApproval−0.7%+0.1%
Oct 29, 2015SEEBRI NEOHALERApproval−0.7%−0.8%
Aug 24, 2015PROMACTA KITApproval−2.5%−0.3%
Jul 7, 2015EntrestoApproval+0.4%+7.4%
Mar 30, 2015JADENUApproval−1.8%+0.9%
Jan 21, 2015CosentyxApproval−4.6%−4.3%
May 15, 2014IZBAApproval+0.7%+0.8%
Apr 29, 2014ZYKADIAApproval+1.9%+2.7%
Apr 28, 2014PURIXANApproval+2.3%+3.9%
May 29, 2013MEKINISTApproval−0.4%−3.2%
Dec 21, 2012ADASUVEApproval−1.1%−0.7%
Aug 29, 2012AFINITOR DISPERZApproval−0.9%+1.0%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
LXH254Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaPhase 2Active not recruiting134Feb 2, 2027
LEE011Ribociclib (LEE011) Rollover Study for Continued AccessPhase 2Active not recruiting22Feb 1, 2027
AlpelisibStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerPhase 2Active not recruiting69Jan 29, 2027
AlpelisibStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Phase 3Active not recruiting210Jan 28, 2027
JDQ443Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationPhase 2Active not recruiting344Jan 25, 2027
everolimusRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 3Active not recruiting206Dec 30, 2026
FabhaltaIptacopan in Patients With ANCA Associated VasculitisPhase 2Active not recruiting84Dec 30, 2026
AAA617A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCPhase 2Active not recruiting49Dec 23, 2026
AAA617Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionPhase 2Active not recruiting23Dec 14, 2026
PelacarsenAn Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Phase 3Terminated41Oct 15, 2026
JDQ443Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationPhase 2Terminated74Sep 28, 2026
YTB323An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusPhase 2Completed21Sep 24, 2026
JDQ443Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerPhase 3Terminated95Sep 3, 2026
FabhaltaA Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationPhase 2Completed168Aug 19, 2026
cyclosporineA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)Phase 3Terminated53Aug 6, 2026
TQJ230Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDPhase 3Completed8,323Jul 16, 2026
IlarisA Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerPhase 2Completed41Jul 6, 2026
KAE609 (Cipargamin)Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)Phase 2Completed95Jun 17, 2026
BION-1301 Single DoseSafety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)Phase 2Completed103Jun 10, 2026
RibociclibFirst-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerPhase 2Completed74May 30, 2026
RibociclibA Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerPhase 3Active not recruiting5,101May 29, 2026
RhapsidoA Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesPhase 3Active not recruiting362May 22, 2026
CPK850A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaPhase 2Completed12May 12, 2026
FabhaltaEfficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyPhase 3Completed34Apr 11, 2026
abelacimabA Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTEPhase 3Terminated417Apr 10, 2026
Ribociclib + Letrozole OR FulvestrantRibociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypePhase 3Terminated61Mar 26, 2026
TQJ230Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDPhase 3Completed422Mar 25, 2026
FabhaltaStudy of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 2Terminated81Mar 19, 2026
TrametinibPaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic CancerPhase 2Terminated20Mar 3, 2026
TIN816 70 mg lyophilisate powderPhase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)Phase 2Completed316Feb 25, 2026
CosentyxEfficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical RemissionPhase 3Completed151Feb 24, 2026
IlarisEvaluation of Canakinumab in High-Risk Former-SmokersPhase 2Completed41Feb 4, 2026
MetforminA Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial CarcinomaPhase 2Completed · results62Feb 4, 2026
NGI226A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles TendinopathyPhase 2Completed45Feb 3, 2026
Trametinib tabletTrametinib in the Treatment of Complicated Extracranial Arterial Venous MalformationPhase 2Completed25Feb 2, 2026
Sacubitril-valsartanAngiotensin-Neprilysin Inhibition in Hemodialysis InitiationPhase 2Completed45Jan 31, 2026
LDK378An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementPhase 2Completed32Jan 29, 2026
20 mg baclofen vaginal suppository daily per vaginaVaginal Baclofen Suppositories in Chronic Pelvic PainPhase 2Completed39Jan 1, 2026
TrastuzumabTrastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)Phase 3Terminated27Dec 23, 2025
DiovanClinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney DiseasePhase 2Completed60Dec 20, 2025